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Abstract
Background: Early detection of esophageal secondary primary tumors (SPTs) in
head and neck squamous cell carcinoma (HNSCC) patients could increase patient
survival. The purpose of this study was to determine the diagnostic yield of esopha-
geal SPTs using Lugol chromoendoscopy.
Methods: A systematic review of all available databases was performed to find all
Lugol chromoendoscopy screening studies.
Results: Fifteen studies with a total of 3386 patients were included. The average
yield of esophageal-SPTs in patients with HNSCC was 15%. The prevalence was
the highest for patients with an index hypopharyngeal (28%) or oropharyngeal
(14%) tumor. The esophageal-SPTs were classified as high-grade dysplasia in 49%
of the cases and as invasive carcinoma's in 51%.
Conclusion: Our results show that 15% of the patients with HNSCC that under-
went Lugol chromoendoscopy were diagnosed with an esophageal-SPT. Based on
these results there is enough evidence to perform Lugol chromoendoscopy, espe-
cially in an Asian patient population.
KEYWORDS
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1 | INTRODUCTION
Part of the mortality of patients treated for head and neck
squamous cell carcinoma (HNSCC) is caused by the occur-
rence of second primary tumors (SPTs).1 Risk factors for their
development include alcohol and tobacco use, age, and the
sub-location of the index tumor (eg, hypopharynx).2 Most
SPTs in patients with HNSCC occur in the head and neck
region, esophagus, and lungs.1,3–6 The risk of esophageal
cancer after HNSCC treatment is an 8-fold to 22-fold greater
than in the general population.7–9 These SPTs are often diag-
nosed in advanced stages, which lead to a very low 5-year
survival rate for affected patients.6,10–12 The prevalence of
esophageal-SPTs in patients with HNSCC is estimated to
range from 0% to 22%.13
The occurrence of esophageal-SPTs in patients with
HNSCC is often explained by field cancerization of the
entire upper aerodigestive tract.14,15 The theory of field can-
cerization states that the mucosal field around the index
tumor possesses subtle histologic and genetic changes that
increase the risk of synchronous and metachronous malig-
nancies. These subtle tissue changes are thought to be the
effect of exposure to accumulating carcinogens (eg, alcohol
and tobacco).10
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Early diagnosis and treatment of an esophageal-SPT may
improve the overall outcome of patients with HNSCC.5,10,16
It has even been suggested that its treatment will affect patient
survival more than the index HNSCC tumor.5 Esophageal
carcinomas can remain asymptomatic for a long time during
development. A result of this is that many patients’ SPTs only
seek medical attention when the tumor is in advanced stages
development.17 Routine screening of the esophagus in the
work-up and follow-up of patients with HNSCC could poten-
tially detect more early stage esophageal-SPTs.18–20
The diagnosis of esophageal-SPTs may impact the man-
agement of both tumors.13 Early stage esophageal-SPTs may
benefit from less invasive endoscopic resection, which can
be performed without compromising the treatment of the
HNSCC.21 However, advanced esophageal-SPTs are often
diagnosed metachronously and will typically be managed by
chemoradiotherapy and surgery.22 The treatment of the
index HNSCC could also hinder that of the esophageal can-
cer due to treatment sequelae or restrictions to therapeutic
options. When possible, personalized treatment should be
focused on both tumors.22,23
Endoscopic techniques to screen the esophagus have
undergone major improvements over the last decades.10
White-light endoscopy is deemed to be insufficient for the
detection of superficial cancerous lesions in asymptomatic
patients.9,10 However, studies with image-enhanced endos-
copy, which includes Lugol's stain, have shown very promis-
ing results. Lugol's stain isolates abnormal “mucosal islands”
within otherwise normal esophageal tissue, enabling targeted
biopsy.9 Lugol chromoendoscopy has a high diagnostic accu-
racy. When combined with narrow band imaging (NBI), it is
reported to have a sensitivity of 94.7% and a specificity of
90.4% to detect early stage esophageal lesions.24,25
Based on these results, many clinics in Asia implemen-
ted esophageal-SPT screening in patients with HNSCC.10
Recently, the French Society of Otorhinolaryngology recom-
mended routine flexible white-light esophageal endoscopy
in the workup of patients with oropharyngeal and hypophar-
yngeal HNSCC or chronic alcohol use.13 The addition of
Lugol’s stain was recommended. They also suggested to per-
form routine screening for metachronous esophageal-SPTs
in the follow-up of patients with HNSCC.9
Esophageal Lugol chromoendoscopy is not widely used
in the management of patients with HNSCC in the Western
world. We performed a systematic review on studies that
used Lugol chromoendoscopy to detect esophageal-SPTs in
patients with HNSCC. Our main objective was to investigate
the yield of Lugol chromoendoscopy for patients with head
and neck cancer in general, but also for specific head and
neck sub-locations. A second aim was to investigate whether
current data from non-Asian patient populations provide
enough evidence to justify Lugol chromoendoscopy screen-
ing for esophageal-SPTs in patients with HNSCC in the
Western world.
2 | MATERIALS AND METHODS
2.1 | Literature search and selection criteria
We searched the Embase, Medline (including PubMed), Web
of Science, Cochrane, and Google Scholar databases for rele-
vant studies. The search was performed in April 2017 without
a limit on publication date. The following keywords were
used for the search: “second/multiple primary tumor,” “esoph-
ageal cancer,” and “head and neck cancer.” We limited our
search to studies written in English and on humans. Duplicate
studies were removed. The remaining citations were reviewed
(by OB) bases on title and abstract and in second stage on full
text. We included studies that investigated the use of Lugol
chromoendoscopy to detect esophageal SPTs in patients with
HNSCC. We excluded studies primarily designed as case
reports or reviews. The next paragraph presents our full elec-
tronic search strategy for the Embase database (see e-content
1 in the Supplement for full search strategy).
(“second cancer”/exp OR “multiple cancer”/de OR
(((Metachronous OR Synchronous OR Second* OR Multiple
OR double OR triple OR quadruple OR quintuple OR sub-
sequen* OR Simultan*) NEAR/6 (tumo* OR primary OR
malignan* OR carcin* OR neoplas* OR cancer*))):ab,ti) AND
(“esophagus tumor”/exp OR “esophagus”/exp OR “esophagus
examination”/exp OR (esophag* OR oesophag* OR (upper
NEXT/3 (aerodigest* OR digest*))):ab,ti) AND (“head and
neck tumor”/exp OR “larynx tumor”/exp OR ((“head”/exp OR
neck/exp) AND “primary tumor”/de) OR (((lip OR mouth OR
oral OR nose OR nasal OR tongue OR tonsil OR nasopharyn*
OR oropharyn* OR hypopharyn* OR pharyn* OR laryn* OR
head OR neck) NEAR/10 (tumo* OR primary OR malignan*
OR carcin* OR neoplas* OR cancer* OR primar*))):ab,ti)
AND [english]/lim NOT ([animals]/lim NOT [humans]/lim).
2.2 | Assessment of study quality
The methodological quality and risk of bias of the selected
Lugol chromoendoscopy screening studies was tested
(by OB) with the methodological index for non-randomized
studies (MINORS).26 Its relevance to the current topic was
determined using a 3-criterion checklist, including (1) impact
factor of publishing journal and thus an indication of quality
of peer review, (2) data on the prevalence of esophageal-SPT
per head and neck sub-location, and (3) clarity of the text
(Table 1). The total score of both the MINORS scale and rele-
vance criteria was used as a quality score. Based on this score,
the quality was classified as low (total score ≤ 10 points),
medium (total score 11-14 points), or high (total score ≥ 15
points). Studies of medium and high quality were included
for further analysis and low-quality studies were excluded.
2.3 | Data extraction
Data from all included studies were extracted onto record
forms (by OB) and results were summarized as a Preferred
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Reporting Items for Systematic Reviews and Meta-Analyses
check list and flowchart.27 The total prevalence of diagnosed
esophageal-SPTs was recorded as primary outcome. An
esophageal-SPT was defined as an esophageal lesion classi-
fied as category 4 and 5: high-grade dysplasia (HGD) or
carcinoma. When possible 3 secondary outcomes were
recorded: (1) the SPT prevalence per sub-location of the
index head and neck tumor (oral cavity, oropharynx, hypo-
pharynx, larynx, nasopharynx, and other) and per tumor
stage (0-4) of the index tumor; (2) whether the SPTs were
diagnosed synchronously (≤6 months after diagnosis of
index tumor, in some cases simultaneously) or metachro-
nously (>6 months after diagnosis of index tumor); and
(3) in which stage of development the SPTs was according
to the Vienna classification of gastrointestinal epithelial
neoplasia.28 Finally, first author, country of study popula-
tion, year of publication, study design, and population size
were also recorded.
2.4 | Statistical analysis
Data were reported as counts and percentages. The SPT
prevalence was calculated for each study as the total number
of detected SPTs divided by the total population that was
screening in the particular study. In studies where the SE
was not reported, we calculated it from the prevalence using
the following formula: SE = √p(1 − p)/n; in which p is the
prevalence and n is the total number of patients with ESCC
that were screened for head and neck SPTs. Review
Manager software (version 5.3) was used for meta-analysis.
Random effects model was used to calculate the pooled
prevalence. I2 was used to evaluate the level of heterogeneity
between studies. Subgroup analyses were performed for
specific head and neck cancer sub-locations.
3 | RESULTS
3.1 | Study selection, quality assessment, and
characteristics
Results of our search query for eligible qualitative Lugol
chromoendoscopy screening studies are presented in
Figure 1. The search identified 4077 citations. After remov-
ing duplicates 2241 citations were reviewed. Based on
review of title and abstract, 1859 citations were excluded.
The remaining 382 studies were reviewed for their eligibility
by reviewing the full text. This revealed 96 studies that
screened a population of patients with HNSCC for esopha-
geal SPTs. Reasons for exclusion of other studies are men-
tioned in Figure 1. Review of the 96 screening studies
resulted in the selection of 23 Lugol chromoendoscopy
screening studies (Table 2).21,22,25,29–48 Most other screening
studies were performed with only white-light endoscopy (eg,
triple-endoscopy) or with the use of PET/CT.
The combined quality score of the MINORS and rele-
vance criteria qualified 15 studies as medium or high quality
and these were included in the present review.21,22,25,29–40
The remaining studies of low quality were excluded. The
methodological quality assessment using MINORS resulted
in scores ranging from 6 to 11 points (median 8 and maximal
possible score 16). The relevance criteria score ranged from
0 to 5 points (median 3 and maximal possible score 6).
Twelve of the studies included (80%) were performed in
Asia (Korea, Japan, and Taiwan) and the remaining 3 in
TABLE 1 Relevance criteria
Score
Criteria 0 1 2
Impact factor <2 2-3.9 ≥4
Sub-location No - Yes
Text clarity Low Medium High
FIGURE 1 Study selection process. *, Embase, Medline, Web of Science,
Cochrane, and Google Scholar; HN, head and neck; MINORS,
methodological index for non-randomized studies; NBI, narrow band
imaging; SPT, multiple primary tumor; WL, white light
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Switzerland, France, and Brazil. Nine studies were performed
within the last decade and all studies within the last 2 decades.
Most studies collected data prospectively (13, 87%). The
study populations ranged from 40 to 676 patients (median
171) and the total number of patients was 3386. All studies
used similar methods by applying 10-40 mL of 0.8%-3.0%
Lugol's solution on the esophageal mucosa.
3.2 | Prevalence
The average prevalence of esophageal-SPTs in patients with
HNSCC of the 15 included studies was 15.2% (413 of 3386,
95% CI: 11.4-19.0) (Figure 2). The 3 studies with the highest
prevalence included only or mostly patients with a hypo-
pharyngeal index tumor.21,22,33 Two Japanese studies only
included patients with oral cavity tumors.30,39 The average
esophageal-SPT prevalence of the 12 Asian studies was
17.7% (358 of 2627, 95% CI: 12.7-22.7). This was higher
than the average of the three non-Asian studies: 6.0% (55 of
759, 95% CI: 2.3-9.7).
3.3 | Prevalence per sub-location
Nine Asian studies reported data of esophageal-SPTs per sub-
location of the index HNSCC (Figure 3).21,22,29–32,38–40 The
prevalence of esophageal-SPTs was the highest in patients
with hypopharyngeal index tumors, followed by patients with
oropharyngeal, oral cavity, and laryngeal and nasopharyngeal
tumors. The average prevalence of esophageal lesions in
patients with hypopharyngeal tumors of seven studies was
28.0% (161 of 574, 95% CI: 22.5-33.5). Five studies reported
an average of 14.0% (35 of 308, 95% CI: 5.4-22.5)
esophageal-SPTs in patients with oropharyngeal tumors. The
diagnostic yield of Lugol chromoendoscopy in patients with
oral cavity tumors was 7.2% (47 of 637, 95% CI: 3.2-11.2).
For patients with laryngeal index tumors the rate of
esophageal-SPTs was 3.4% (19 of 474, 95% CI: 1.8-5.4).
Four studies reported only 2 esophageal-SPTs in 109 patients
with nasopharyngeal tumors and none were found in patients
with other index tumors (eg, glandular tumors).
3.4 | Time to diagnosis
Most studies only performed endoscopic screening of the
esophagus in the work-up of the index HNSCC tumor and
thus only diagnosed synchronous, or even simultaneous
esophageal-SPTs. Four studies performed both synchronous
and metachronous esophageal endoscopies.21,32,33,35 Morimoto
et al performed at diagnosis of the HNSCC and annually
TABLE 2 Characteristics and MINORS + relevance scores of all 23 Lugol chromoendoscopy screening studies
Score
Authors Country Year Design N MINORS Relevance Total Quality
Included studies
Gong et al29 Korea 2016 Pro 458 10 5 15 High
Wang CH et al25 Taiwan 2014 Pro 294 11 3 14 Medium
Wang, Wang, et al22 Taiwan 2013 Pro 180 9 5 14 Medium
Ikawa et al30 Japan 2012 Pro 171 8 4 12 Medium
Wang, Lee, et al31 Taiwan 2011 Pro 315 11 5 16 High
Morimoto et al21 Japan 2010 Pro 64 7 4 11 Medium
Fukuhara et al32 Japan 2010 Pro 157 8 4 12 Medium
Lee et al33 Taiwan 2009 Pro 44 11 4 15 High
Boller et al34 Switzerland 2009 Pro 40 11 3 14 Medium
Dubuc et al35 France 2006 Pro 393 10 3 13 Medium
Hashimoto et al36 Brazil 2005 Pro 326 10 4 14 Medium
Muto, Nakane, et al37 Japan 2002 Pro 78 9 4 13 Medium
Tanabe et al38 Japan 2001 Retro 134 8 3 11 Medium
Fukuzawa et al39 Japan 1999 Pro 56 7 4 11 Medium
Horiuchi et al40 Japan 1998 Retro 676 7 4 11 Medium
Excluded studies
Laohawiriyakamol et al41 Thailand 2014 Pro 89 10 0 10 Low
Komínek et al42 Czech R. 2013 Pro 132 9 0 9 Low
Chow et al43 China 2009 Retro 118 7 2 9 Low
Muto, Hironaka, et al44 Japan 2002 Retro 389 6 1 7 Low
Tincani et al45 Brazil 2000 Pro 60 7 0 7 Low
Ina et al46 Japan 1994 Pro 127 7 2 9 Low
Chisholm et al47 China 1992 Pro 37 7 0 7 Low
Shiozaki et al48 Japan 1990 Pro 178 7 2 9 Low
Abbreviations: MINORS, methodological index for non-randomized studies; N, number of patients with head and neck cancer included; Pro, prospective; Retro,
retrospective; Year, year of publication.
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during follow-up.21 Eighteen (69.2%) of all SPTs were diag-
nosed synchronously and 8 (30.8%) metachronously. Fukuhara
et al found a similar distribution between synchronously diag-
nosed SPTs (n = 17 [60.7%]) and those that were diagnosed
metachronously (n = 9 [32.1%]).32 The two other studies also
metachronous endoscopies, but did not separately mention the
synchronous or metachronous diagnostic yield of Lugol
chromoendoscopy.33,35
3.5 | Vienna classification
Eight studies differentiated between esophageal-SPTs classi-
fied as category 4 (HGD) or 5 (carcinoma).21,25,29,31,33–36
The remaining studies either did not mention the category or
only mentioned category 5. Almost half of all esophageal-
SPTs found in these 8 studies (48.6%, range 22.2-100.0)
were category 4 lesions, HGD. That was approximately the
same for Asian (43.3%, n = 5) and non-Asian (57.4%,
n = 3) studies. Three of these 7 studies also differentiated
the esophageal carcinoma's in low-stage (stages I and II) and
high-stage (stages III and IV) esophageal tumors.21,29,31
Their combined data show that 53.9% (41/76) of all esopha-
geal carcinoma's were classified as low stage and 46.1%
(35/76) as high stage.
3.6 | Prevalence per index tumor stage
Three Asian studies also reported the prevalence of
esophageal-SPTs in patients with HNSCC per tumor stage
of the index tumor.21,29,39 There were a total of 5 (3.1%,
95% CI: 0.3-5.8) esophageal-SPTs in 150 patients with stage
I HNSCC, 28.8% (95% CI: −5.7 to 63.3) esophageal-SPTs
in patients with stage II HNSCC, 5.34% (95% CI: 1.1-9.6)
esophageal-SPTs in stage III HNSCC, and 22.5% (95% CI:
−2.3 to 47.3) in patents with a stage IV index HNSCC.
4 | DISCUSSION
To the best of our knowledge, this is the first systematic
review on the diagnostic yield of Lugol chromoendoscopy
for esophageal SPTs in patients with HNSCC. Our main
findings show that on average, 15% of the patients with
primary HNSCC that underwent Lugol chromoendoscopy
were diagnosed with an esophageal-SPT. We found that the
prevalence was the highest for patients with hypopharyngeal
index tumors.
There is a large discrepancy between the prevalence of
esophageal-SPTs in patients with HNSCC found with Lugol
chromoendoscopy screening (15%, 95% CI: 11-19) and
the prevalence of retrospective non-screening studies
(1%-6%).6,7,49–53 This was also noted by Wang, Lee, et al.31
This discrepancy could indicate that without an active
screening program, esophageal-SPTs are underdiagnosed in
patients with HNSCC.7 Multiple studies state that the
occurrence of esophageal-SPTs negatively influences patient
survival, especially in patients with advanced esophageal-
SPTs.23,54–56 Some researchers even claim that SPTs are the
leading cause of treatment failure and death in patients with
HNSCC.31
The hypopharynx, and in particular involvement of the
piriform sinus, is a well-known risk factor for the develop-
ment of esophageal-SPTs.57–60 The results from the present
review also SPTs underlined this. Wang WL et al com-
pared two hypopharyngeal HNSCC cohorts: before and
after implementing pretreatment Lugol chromoendoscopy
esophagus screening.22 Active esophageal screening tripled
the amount of diagnosed esophageal-SPTs (5.3% vs
15.3%). The present study also found esophageal-SPTs in
11% of patients with oropharyngeal cancer, which is also a
known sub-location to be at risk factor for the develop-
ment of an esophageal-SPT.60,61 However, the 2 largest
studies in this review with specific oropharynx data by
Horiuchi et al and Gong et al found relatively low preva-
lence of esophageal-SPTs (7.2% and 2.8%) in this sub-
group of patients.
The finding that up to a third of all esophageal-SPTs
found in the studies by Morimoto et al and Fukuhara
et al were diagnosed metachronously during follow-up could
indicate that the results of the other synchronous studies
FIGURE 2 Overview of prevalence of esophageal-SPTs of 15 Lugol
chromoendoscopy screening studies. Error bars represent 95% confidence
intervals. *, both synchronous and metachronous screening; †, transnasal
Lugol chromoendoscopy; hypo, study included only patients with
hypopharyngeal tumors; oral, study included only patients with oral cavity
tumors; SPT, multiple primary tumor
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underestimate the true prevalence of esophageal-SPTs.21,32
It is also an indication that esophageal screening of patients
with HNSCC should also be performed in the follow-up of
the index tumor. However, the optimal esophageal screening
schedule has yet to be defined.
Approximately 50% of the esophageal lesions found in
this review were classified as HGD. Of the remaining lesions
classified as invasive carcinoma, about half were early stage.
This is similar to the findings from other researchers.22,29,38
Wang, Wang, et al showed that an active screening protocol
diagnosed more HGD lesions and early stage carcinomas,
which significantly reduced the mortality rate of affected
patients.22 This is possibly the result of adjustments of the
treatment strategy aimed at treating 2 instead of 1 tumor and
less invasive endoscopic treatment of the esophageal lesions.
Multiple studies claim that treatment of the esophageal-SPT
increases the survival, especially in patients with early stage
tumors.23,54–56
Five of the included studies in this review used NBI in
addition to Lugol chromoendoscopy.22,25,29,31,33 Wang CH
et al concluded that this combination of both techniques has
the highest diagnostic accuracy to detect esophageal lesions:
a sensitivity of 95%, a specificity of 90%, and an accuracy of
91% (95% CI: 88-94).25 Several other researchers have
investigated the use of full-body 18F-FDG-PET/CT. They
reported a considerably lower diagnostic esophageal-SPT
yield that ranged from 0.43% to 4.85%.62–66 As Kondo
et al also mentioned that PET/CT seems to be an inferior
technique for detection of esophageal-SPTs because it is not
sensitive for early tumors.62
Two of the studies included in this review performed
transnasal Lugol chromoendoscopy.25,33 Tumor-related air-
way obstruction or postradiation trismus sometimes make the
oropharyngeal passage difficult to reach with conventional
endoscopes. The transnasal route bypasses this problem.
Transnasal Lugol chromoendoscopy has the additional advan-
tage that it can be performed in unsedated patients and that it
even has a higher completion rate than conventional
endoscopy.67
The prevalence of SPTs after HNSCC in the existing
literature varies greatly geographically. In Asia, second pri-
mary gastrointestinal tract malignancies are more common
FIGURE 3 Overview of prevalence of esophageal-second primary tumors (SPTs) per sub-location of index head and neck squamous cell carcinoma:
A, hypopharynx; B, oropharynx; C, oral cavity; and D, larynx. Nine Asian studies with sub-location specific data. Fukuhara et al and Morimoto et al screened
both synchronously and metachronously. Error bars represent 95% confidence intervals
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after index HNSCC than in the Western world.2 It is thought
that Asians have a higher exposure to risk factors such as
smoking and alcohol use. Other risk factors such as hot bev-
erage drinking and betel quid chewing and genetic suscepti-
bility have also been suggested to play a part.68 As a result,
the literature on this topic, including the studies of this
review, is mostly from Asian countries. In the present
review, only 3 studies were non-Asian. This prohibits us to
draw bold conclusions and extrapolate results on the useful-
ness of Lugol chromoendoscopy in a non-Asian patient pop-
ulation, as also stated by Morimoto et al.21
Another limitation is the quality of the included studies.
As the quality of a review greatly relies on the quality of the
included data, we excluded studies of low quality. Although
the remaining 15 studies were all similar in methodology
and research question, there was some heterogeneity among
the studies in the subsites of the index HNSCC tumors that
were included. This might have had an influence on the
average prevalence of all studies. However, the 4 largest
studies (n = 326-676) with the highest weight on the aver-
age fortunately included all sub-locations. A final potential
limitation is that the study selection and quality assessment
was performed by 1 reviewer. The overall study quality
could have benefited from an assessment by 2 independent
reviewers.
In conclusion, this review has shown that the prevalence
of esophageal SPTs in patients with head and neck cancer is
high, especially for patients with a hypopharyngeal and oro-
pharyngeal index tumor. A large percentage of esophageal
lesions were found in early stage of development. Literature
shows that this group of patients could significantly benefit
from dual tumor treatment, resulting in an increased 5-year
survival rate. Based on our results, there appears to be strong
evidence to perform Lugol chromoendoscopy screening in
an Asian patient population. More screening studies are
needed to confirm the same for the Western world, and
Lugol chromoendoscopy holds the potential to increase the
overall survival rate of patients with head and neck cancer,
due a lowered SPT-specific mortality.
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